LPL Financial
ADAP

LPL Financial’s Adaptimmune Therapeutics ADAP Stock Holding History

LPL Financial’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-183,479
Closed -$98.8K – 5346
2024
Q4 		$98.8K Buy
183,479
+94,623
+106% +$69K ﹤0.01% 5000
2024
Q3 		$84.4K Sell
88,856
-110,000
-55% -$125K ﹤0.01% 4923
2024
Q2 		$194K Buy
198,856
+90,000
+83% +$98.8K ﹤0.01% 4582
2024
Q1 		$172K Buy
+108,856
New +$131K ﹤0.01% 4542

Other funds holding ADAP

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LPL Financial's ADAP Position: Q1 2025 in Review

LPL Financial sold out of Adaptimmune Therapeutics (ADAP) in Q1 2025, closing a stake of 183,479 shares — an estimated $98.8K sold.

LPL Financial first reported a position in ADAP in Q1 2024 and held it in 4 quarters. The position peaked at $194K in Q2 2024. 67 funds tracked by Wall St. Rank hold ADAP as of Q1 2025.

  • LPL Financial reported no remaining Adaptimmune Therapeutics position as of Q1 2025 after selling out during the quarter.
  • LPL Financial sold 183,479 Adaptimmune Therapeutics shares in Q1 2025, an estimated $98.8K.
  • LPL Financial first reported a position in Adaptimmune Therapeutics in Q1 2024 and held it in 4 quarters.
  • LPL Financial's Adaptimmune Therapeutics position peaked at $194K in Q2 2024.
  • 67 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2025.

Based on LPL Financial's 13F filing for Q1 2025, filed 7 May 2025.